First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.
Fiche publication
Date publication
mars 2021
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Pr GARNACHE-OTTOU Francine
Tous les auteurs :
Anna F, Bole-Richard E, LeMaoult J, Escande M, Lecomte M, Certoux JM, Souque P, Garnache F, Adotevi O, Langlade-Demoyen P, Loustau M, Caumartin J
Lien Pubmed
Résumé
CAR-T cells immunotherapy is a breakthrough in the treatment of hematological malignancies such as acute lymphoblastic leukemia (ALL) and B-cell malignancies. However, CAR-T therapies face major hurdles such as the lack of tumor-specific antigen (TSA), and immunosuppressive tumor microenvironment sometimes caused by the tumorous expression of immune checkpoints (ICPs) such as HLA-G. Indeed, HLA-G is remarkable because it is both a potent ICP and a TSA. HLA-G tumor expression causes immune escape by impairing innate and adaptive immune responses and by inducing a suppressive microenvironment. Yet, to date, no immunotherapy targets it.
Mots clés
adoptive, antigens, biomarkers, carbohydrate, chimeric antigen, immunotherapy, receptors, tumor, tumor escape, tumor-associated
Référence
J Immunother Cancer. 2021 Mar;9(3):